[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycemia-in-pregnant-diabetic-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycemia-in-pregnant-diabetic-patients":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100605394",false,"NCT07161947","Shanghai Clinical Cohort of Hyperglycemia in Pregnancy","Shanghai Clinical Cohort-Hyperglycemia in Pregnancy (Reserved)","SHINE","Inclusion Criteria:\n\n* Pregnant individuals who provide written informed consent\n* At enrollment, meet one of the following:\n\n  1\\. Gestational diabetes mellitus (GDM) diagnosed by a 75-g oral glucose tolerance test (OGTT) using Chinese Diabetes Society (CDS) 2024 thresholds (any one of: fasting plasma glucose ≥5.1 mmol\u002FL, 1-h ≥10.0 mmol\u002FL, or 2-h ≥8.5 mmol\u002FL); or 2. Pre-gestational diabetes (type 1 or type 2) documented prior to pregnancy or meeting diabetes criteria at the first prenatal visit (e.g., fasting ≥7.0 mmol\u002FL, 2-h OGTT ≥11.1 mmol\u002FL, or HbA1c ≥6.5%); or 3. At high risk for GDM, defined a priori as ≥1 of the following: prior GDM; prior macrosomic infant (≥4,000 g); pre-pregnancy BMI ≥24 kg\u002Fm²; age ≥45 years; high-density lipoprotein cholesterol \\\u003C1 mmol\u002FL, and\u002For triglyceride levels \\>2.8 mmol\u002FL; first-degree family history of diabetes; polycystic ovary syndrome (PCOS); history of coronary heart disease; chronic hypertension and repeated positive fasting urinary glucose in early pregnancy\n* Age ≥18 years at the time of consent\n* Willing and able to attend postpartum assessments (OGTT at 6 weeks, 12 months, and annually thereafter), with planned follow-up ≥3 years\n\nExclusion Criteria:\n\n* Current or history of illicit drug use or substance abuse\n* Presence of an active infectious disease, including but not limited to: viral hepatitis, sexually transmitted infections or tuberculosis\n* Any other condition which, in the judgment of the investigator, would make the subject unsuitable for enrollment in the study","FEMALE","18 Years",{"count":19,"type":20},4000,"ESTIMATED","10 Years","OBSERVATIONAL","Establish a high-quality clinical cohort of hyperglycemia in pregnancy. Develop subtype-specific, end-to-end standards for diagnosis, treatment, and follow-up across the preconception, pregnancy, and postpartum phases. These standards will lay a solid foundation for efficient, high-quality clinical research.",[25,26],"Hyperglycemia in Pregnant Diabetic Patients","Gestatiaonl Diabetes Mellitus","RECRUITING","2025-09-08",{"date":30,"type":31},"2025-09-09","ACTUAL",{"date":33,"type":31},"2025-04-01",{"date":35,"type":20},"2027-12-31",{"name":37,"class":38},"Shanghai General Hospital, China","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100602620","NCT07125885","Gongji Pregnancy Endorine Cohort Study","Serological, Metabolomic, and Genomic Studies of Endocrine Disorders in Pregnancy","GREAT","Inclusion Criteria:\n\n* Women preparing for pregnancy or pregnant women or within 1 year after giving birth\n* Age ≥ 18 years old\n* Signed the informed consent form to voluntarily enroll in the management follow-up\n\nExclusion Criteria:\n\n* Individuals who are unable to communicate normally and those who are unwilling to cooperate\n* Pregnant women with severe organic diseases or mental illnesses\n* Any condition deemed by the investigator to affect eligibility for the study","50 Years",{"count":49,"type":20},3000,"To explore the relationship between genetic factors, lifestyle, and drug interventions and the occurrence, development, adverse pregnancy outcomes, and postpartum maternal-infant outcomes of gestational endocrine diseases.",[26,52,25],"Thyroid Disease Pregnancy","2025-08-09",{"date":55,"type":31},"2025-08-15",{"date":57,"type":31},"2023-05-05",{"date":59,"type":20},"2043-12-31",{"name":37,"class":38},""]